Stocks in play: Helix BioPharma Corp.
Will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15. Helix BioPharma Corp. shares T.HBP are trading unchanged at $0.21.
Read:
Shortage Looms for Carbon Credits Market Projected to Reach $2.4 Trillion in 5 Years
Gold Reshuffle: Mining Industry Transforms Amidst Global Changes
The Inflation Reduction Act Sparks Domestic Lithium Mining Boom
Navigating the Surge in Pancreatic Cancer: The Innovative Strategies Offering New Hope
Pancreatic Cancer's Alarming Surge in Young Adults Sparks Research into New Treatments